LKT Labs

Biochemicals for Life Science Research

BYL719

BYL719

Product ID B9700
Cas No. 1217486-61-7
Purity ≥99%, ≥99%ee
Product Unit SizeCostQuantityStock
1 mg $63.00 In stock
5 mg $116.00 In stock
25 mg $173.00 In stock
100 mg $446.00 In stock
Bulk Quote

Quicklinks

Description

BYL-719 is an ATP-competitive oral PI3K inhibitor selective for the p110α isoform that is activated by a mutant PIK3CA gene in HER2+ breast cancers and gastric cancers. BYL-719 exhibits anticancer chemotherapeutic activity and inhibits proliferation in a variety of cell lines. IGF1 and neuregulin 1 activate mTOR, a downstream target of PI3K that mediates resistance to BYL-719 in some in vitro cancer models. This compound also decreases invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer.

Product Info

Cas No.

1217486-61-7
Purity

≥99%, ≥99%ee
Formula

C19H22F3N5O2S
Formula Wt.

441.47
Chemical Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide
IUPAC Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide
Synonym

Alpelisib, NVP-BYL719, BYL-719
Solubility

DMSO 88 mg/mL (199.33 mM) Ethanol 2 mg/mL (4.53 mM) Water Insoluble
Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

B9700 MSDS PDF
Info Sheet

B9700 Info Sheet PDF

References

Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

Elkabets M, Vora S, Juric D, et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer. Sci Transl Med. 2013 Jul 31;5(196):196ra99. PMID: 23903756.

Abstract: Juric. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. American Association for Cancer Research. 2012.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • P698574

    Prolylrapamycin

    Rapamycin analog
  • E7329

    Ethoxyquin

    Quinoline, food preservative; HSP90 inhibitor.<...

    ≥90%
  • R5700

    Ro 61-8048

    Kynurenine 3-hydroxylase inhibitor.

    ≥99%
  • B1973

    Besifloxacin Hydrochloride

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • L1981

    Leucokinin VIII

    Peptide found in insects.

    ≥95%
  • A5032

    D,L-Aminoglutethimide

    Aromatase inhibitor.

    ≥98%
  • P3465

    Piperine

    Alkaloid found in black and long peppers; TRPV1...

    ≥95%
  • A706840

    ARV-825

    Degrades of BET proteins.

    ≥99%
  • P2857

    Phorbol-12-myristate-13-acetate

    PKC activator, carcinogen.

    ≥98%
  • D6958

    Droloxifene Citrate

    Tamoxifen analog; SERM.

    ≥98%
  • C0221

    Caffeine

    Xanthine alkaloid found in coffee, tea, and oth...

    ≥98%
  • C1868

    Cerebellin

    Peptide, involved in synapse formation and cell...

    ≥95%
  • M4452

    MLN2480

    Raf inhibitor.

    ≥98%
  • P327211

    Pifithrin-α Hydrobromide

    p53 inhibitor

    ≥98%
  • K0023

    K252c

    Staurosporine analog; PKC and PKA inhibitor.

    ≥98%
  • M3598

    Mizoribine Hydrobromide

    IMPDH inhibitor.

    ≥98%
  • A7208

    Ascomycin

    FK506 analog; calcineurin inhibitor.

    ≥98%
  • N5767

    Norethindrone

    Steroid hormone, contraceptive; PR agonist.

    ≥98%
  • S8010

    [Nle11]-Substance P

    Endogenous tachykinin peptide, involved in infl...

    ≥95%
  • C4000

    CK-636

    Arp2/3 inhibitor.

    ≥98%